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Influenza Update 
The Iowa Department of Public Health (IDPH) is encouraging all Iowans to get their seasonal influenza vaccination.  “We 
want everyone to know the most effective way to stop the spread of the flu is to get the flu vaccine each year,” said Dr. 
Patricia Quinlisk of the Iowa Department of Public Health.  “IDPH and the Centers for Disease Control and Prevention 
recommend influenza vaccination for everyone 6 months of age and older.”    
  
This year’s vaccine will protect against the three main influenza viruses that research indicates will cause the most 
illness.  This season’s flu vaccine will protect against 2009 H1N1, an A-H3N2, and a B-Brisbane virus. 
  
Even healthy people, including healthy children and young adults, can get very ill from the flu and can spread the flu to 
others.  By getting a yearly flu vaccine you can protect yourself from illness, and protect those around you. It is especially 
important to be vaccinated if you have vulnerable people in your household such as babies, children with asthma, and 
the elderly.  
  
Influenza is a respiratory illness that most often causes fever, headache, extreme tiredness, muscle pain, nonproductive 
coughing, sore throat, and a runny nose. Occasionally, diarrhea can accompany the respiratory symptoms in children.  
 
The flu virus is spread when people who are ill cough or sneeze without covering their mouths and noses, sending tiny 
droplets of respiratory secretions into the air for others to breathe in and get sick.  A person can also get the flu by 
touching a surface or object (such as a door handle) that has been touched by someone with the flu (who coughed into 
their hand), and then touching their own mouth, eyes or nose.  
  
The flu vaccine is plentiful this year and is available in both injectable and mist presentation.  
 
For questions regarding the influenza vaccine, call Terri Thornton or Bethany Kintigh at 1-800-831-6293 ext. 2 & 7, 
respectively.  
 
For questions regarding VFC influenza vaccine availability, call Tina Patterson at 1-800-831-6293 ext. 4.  
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2011 - 2012 Influenza Vaccine Recommendations for Children  
6 Months through 8 Years of Age  
Children 6 months through 8 years of age, regardless of influenza vaccine administration history prior to the 2010 - 2011 
influenza season, should be vaccinated accordingly:  
 
o Children that received no doses or with an unknown vaccine history of 2010 - 2011 influenza vaccine should 
receive 2 doses of 2011-2012 influenza vaccine.  
 
o Children that received 1 or more doses of 2010 - 2011 influenza vaccine should receive 1 dose of 2011-2012 
influenza vaccine.  
 
Influenza vaccine dosing algorithm for children  
aged 6 months through 8 years for the 2011-12 influenza season 
 
 
 
Questions and Answers regarding Influenza 
 
Q: How many doses of 2011-2012 influenza vaccine would a 7 year old child need that has received 4 doses of influenza 
vaccine in the past influenza seasons but did not receive influenza vaccine in the 2010-2011 season?  
A: The child should receive 2 doses of 2011-2012 influenza vaccine.  Two doses are necessary to provide 
protection against the strains contained in 2010-2011 and 2011-2012 influenza vaccine.  
 
Q: How many doses would be needed for an 18 month old infant who received influenza vaccine for the first time in the 
2010-2011 season, who should have received 2 doses of influenza vaccine 4 weeks apart because it was their first 
season to receive influenza vaccine?  However, the child only received one dose of 2010-2011 influenza vaccine.  
A: The child should receive one dose of 2011-2012 influenza vaccine this season.  Two doses of 2011-2012 
influenza vaccine are NOT necessary since the influenza vaccine strains did not change from the 2010-2011 
season.  
 
Q: A patient that is 2 years 11 months (35months) old with a history of several wheezing episodes has received influenza 
vaccine in the past but did not receive any influenza vaccine in the 2010-2011 season.  How many doses of 2011- 2012 
influenza vaccine should this patient receive?   
A:  The patient will need 2 doses of the injectable influenza vaccine (due to history of wheezing) separated by at 
least 4 weeks.  Administer a 0.25 ml dose of influenza vaccine since the  patient is 35 months of age.  The second 
dose of influenza vaccine should be administered by at least 4 weeks from the first dose and will be 0.5ml dose 
of influenza vaccine since the child is now 3 years of age.   
 
Recommendations regarding influenza vaccination for persons who report 
allergy to eggs - Advisory Committee on Immunization Practices (ACIP), 2011-12 
influenza season 
The figure below includes recommendations regarding influenza vaccination for persons who report allergy to eggs for 
the 2011-12 influenza season, according to the Advisory Committee on Immunization Practices (ACIP).  Persons who 
have experienced only hives following exposure to egg should receive influenza vaccine with the following additional 
measures. 
 
 
* Persons with egg allergy might tolerate egg in baked products (e.g., bread or cake).  
Tolerance to egg-containing foods does not exclude the possibility of egg allergy. 
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2011-12 Influenza Season 
Vaccine Information by Age Group* 
 
Abbreviations: TIV = trivalent inactivated vaccine; LAIV = live attenuated influenza vaccine; IM = intramuscular; ID = intradermal; IN = intranasal. 
*    Vaccination providers should check Food and Drug Administration–approved prescribing information for 2011–12 influenza vaccines for the most 
updated information. 
†  Information not included in package insert but is available upon request from the manufacturer, Sanofi Pasteur, by telephone, 1-800-822-2463, or    
e-mail, MIS.Emails@sanofipasteur.com. 
§  Children 6 months through 8 years of age require 2 doses of influenza vaccine (administered a minimum of 4 weeks apart) during their first season of 
vaccination to optimize immune response.   
o Vaccination providers should note that, in previous seasons, children 6 months through 8 years who received only 1 dose of influenza vaccine in 
their first year of vaccination require 2 doses the following season.   
o However, because the 2011-12 vaccine strains are unchanged from the 2010-11 season, children in this age group who received at least 
1 dose of the 2010-11 seasonal vaccine will require only 1 dose of the 2011-12 vaccine.   
o Children in this age group who did not receive 1 dose of the 2010-11 seasonal influenza vaccine, or for whom it is not certain whether the 
2010-11 seasonal vaccine was received, should receive 2 doses of the 2011-12 seasonal influenza vaccine. 
¶  For adults and older children, the recommended site of vaccination is the deltoid muscle. The preferred site for infants and young children is the 
anterolateral aspect of the thigh. 
** Age indication per package insert is ≥5 years; however, the Advisory Committee on Immunization Practices recommends Afluria not be used in 
children aged 6 months through 8 years because of increased reports of febrile reactions in this age group. If no other age-appropriate, licensed 
inactivated seasonal influenza vaccine is available for a child aged 5–8 years who has a medical condition that increases the child’s risk for influenza 
complications, Afluria can be used; however, providers should discuss with the parents or caregivers the benefits and risks of influenza vaccination 
with Afluria before administering this vaccine. Afluria may be used in persons aged ≥9 years. 
†† TIV high-dose: A 0.5-mL dose contains 60 µg each of A/California/7/2009 (H1N1)-like, A/Perth/16/2009 (H3N2)-like, and B/Brisbane/60/2008-like 
antigens. 
§§ FluMist is shipped refrigerated and stored in the refrigerator at 35°F–46°F (2°C–8°C) after arrival in the vaccination clinic. The dose is 0.2 mL divided 
equally between each nostril. Health-care providers should consult the medical record, when available, to identify children aged 2–4 years with 
asthma or recurrent wheezing that might indicate asthma. In addition, to identify children who might be at greater risk for asthma and possibly at 
increased risk for wheezing after receiving LAIV, parents or caregivers of children aged 2–4 years should be asked: ―In the past 12 months, has a 
health-care provider ever told you that your child had wheezing or asthma?‖Children whose parents or caregivers answer ―yes‖ to this question and 
children who have asthma or who had a wheezing episode noted in the medical record within the past 12 months should not receive FluMist. 
¶¶  Insufficient data available for use of LAIV in egg-allergic persons. 
***  FluMist is indicated for healthy, nonpregnant persons aged 2–49 years. 
 
Table adapted from MMWR/August 18, 2011/Vol. 60 /No. 32 
 
 
 
 
 
Trade 
name 
 
 
 
Manufacturer 
 
 
 
Presentation 
Mercury 
content 
(µg Hg/0.5 mL 
dose) 
Ovalbumin 
content 
(µg /0.5mL 
dose) 
 
 
Age group 
 
 
 
No. of 
doses 
 
 
 
Route 
TIV Fluzone Sanofi Pasteur 0.25 mL prefilled 
syringe 
0.0 —† 6–35 mos 1 or 2§ IM¶ 
0.5 mL prefilled syringe 0.0 —† ≥36 mos 1 or 2§ IM¶ 
0.5 mL vial 0.0 —† ≥36 mos 1 or 2§ IM¶ 
5.0 mL multidose  vial 25.0 —† ≥6 mos 1 or 2§ IM¶ 
         
TIV Fluvirin Novartis Vaccines 0.5 mL prefilled syringe ≤1 ≤1 ≥4 yrs 1 or 2§ IM¶ 
5.0 mL multidose  vial 25.0 ≤1    
         
TIV Fluarix GlaxoSmithKline 0.5 mL prefilled syringe 0 ≤0.05 ≥3 yrs 1 or 2§ IM¶ 
         
TIV FluLaval ID Biomedical 
Corporation of 
Quebec 
(distributed by 
GlaxoSmithKline) 
5.0 mL multidose  vial 25.0 ≤1 ≥18 yrs 1 IM¶ 
TIV Afluria CSL Biotherapies 
(distributed by 
Merck) 
0.5 mL prefilled syringe 0.0 ≤1 ≥9 yrs** 1 IM¶ 
5.0 mL multidose  vial 24.5 ≤1 
  
 
  
    
   
TIV High-Dose†† Fluzone 
High-Dose 
Sanofi Pasteur 0.5 mL prefilled syringe 
0.0 —† ≥65 yrs 1 IM¶ 
TIV Intradermal Fluzone 
Intradermal 
Sanofi Pasteur 0.1 mL prefilled 
microinjection system 0.0 —† 18–64 yrs 1 ID 
         
LAIV FluMist§§ MedImmune 0.2 mL prefilled 
Intranasal sprayer 
0.0 —¶¶ 2–49 yrs*** 1 or 2§ IN 
IRIS Update 
The Iowa Department of Public Health continues activities to transition to a version of Wisconsin’s Immunization 
Registry (WIR).  Iowa’s Immunization Program staff has been working closely with Hewlett Packard (HP) on project 
details.  The following summarizes the progress as of September 2011:   
o Hardware and software have been purchased and set up to allow application staging for the development and 
test environments. 
o IRIS and HP staff are working to develop and approve Functional Design Documents (FDDs) on various registry 
components.  FDDs include Iowa specifications which allow the vendor to make customizations to meet Iowa’s 
needs.   
o The Immunization Program received a grant to facilitate interoperability between IRIS and electronic health 
records (EHR).  The timing of this grant is ideal as Iowa transitions to the WIR application.  Immunization staff is 
working closely with Health Information Network (HIN) team at IDPH regarding data exchange specifications.  As 
details are available, including file specifications, information will be sent using the electronic IRIS distribution 
list and posted on the IRIS website.  
o Iowa’s User Acceptance Testing (UAT) region is available to allow IDPH staff to begin using components of the 
new IRIS application.   
o IRIS staff will send screen shots of the new system as soon as they are available.  The screen shots will allow 
users to get a sense of the new look and feel of IRIS. 
o Implementation of the new IRIS application is scheduled for June 2012. 
If you have any questions about the new version of IRIS, please feel free to call the IRIS Help Desk at 800-374-3958 or 
Kim Tichy, IRIS Coordinator, at Kimberly.tichy@idph.iowa.gov. 
To receive IRIS updates directly in your inbox, please send a blank e-mail to: join-IRISUSERS@lists.ia.gov 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cerro Gordo County Introduces 
Howie Staywell  
 
 
How do you increase your visibility as a health 
department?  If you are Cerro Gordo County 
Department of Public Health, you introduce Howie 
Staywell. 
 
Howie Staywell was invented while discussing 
influenza marketing this summer and the need to 
create a campaign that resonated well with the 
members of the community.  The idea of a mascot 
came up because it would not only comfort children 
at school-based vaccine clinics, but it would also help to brand the health department.  When people saw Howie 
Staywell, they would make the connection with the Cerro Gordo County Department of Public Health.  
 
Health Department staff voted on the type of mascot they wanted to represent the organization.  Howie Staywell, the 
owl, was chosen because staff thought he looked warm and inviting, yet professional.  
 
A contest was created to allow the public to name him resulting in a lot of creative and innovative names.  It was a great 
feeling to see how the public welcomed this new marketing endeavor.  The result combined two name suggestions 
Howie and Staywell, which is a fabulous play on words, “How we stay well.” 
 
Howie has been a huge hit at the flu clinics.  He serves as a welcoming agent to greet the students and families when 
they arrive at their back-to-school nights.  He also comforts the students when they receive their shot.  Staff has noticed 
students aren’t so apprehensive to get a flu shot or flu mist because they know afterwards they can spend time with 
Howie by giving him a hug or a high five.  
 
Cerro Gordo Public Health says Howie Staywell has been a great addition to the 
department.  He helps to encourage the public to stay healthy and well, while 
adding that personal touch . 
 
 
Do you have a “best practice” you would like to share with the Immunization 
Program?  Contact Sharon Kasper at Sharon.Kasper@idph.iowa.gov or 800-831-
6292 ext. 1. 
 
 
 
 
 
 
 
Howie Staywell assisting at a local flu clinic. 
Local Public Health Billing Project 
 
The Iowa Department of Public Health (IDPH) and HS Medical Billing held four comprehensive billing training programs 
to 149 representatives of local public health agencies (LPHAs) in Iowa.  Seventy-seven of Iowa’s 99 counties were 
represented at the meetings.  
 
This project included the development of a plan for a billing system with the intent of saving program revenue; enable 
programs to reach additional populations, provide vaccines that are not currently offered and to take on new 
immunization initiatives to immunize special under-vaccinated populations with reduced access to vaccination services. 
 
A toolkit was provided to each LPHA, which included the following: 
o Complete guidelines for credentialing an agency and its providers with the appropriate payer organizations. 
o Information, resources, and time requirements to implement a billing program. 
o Technology information regarding software selection, EHR technology and claim submission strategies.  
o Sample forms, policies and guidelines 
for billing requirements of the various 
third party payers.  
 
Evaluations after the trainings showed 95 
percent of the attendees said they felt the 
toolkit would be a valuable resource to help 
them build or expand their billing program, 
and 81 percent said they had a better 
understanding of the billing process as a result 
of the training.  Seventy-six percent of 
agencies reported they were likely to start or 
expand their billing as a result of the trainings.  
 
A copy of the billing toolkit will be sent to 
Local Public Health Agencies that were unable 
to attend.  The Immunization Program field 
staff will deliver these toolkits to agencies in the 
upcoming months. 
 
For more information regarding the billing project or Immunization Program activities, contact  
Marnell Kretschmer at marnell.kretschmer@idph.iowa.gov or 515-281-4917. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Oskaloosa Billing Symposium 
Vaccine Event Reporting System (VAERS)  
The Vaccine Adverse Event Reporting System (VAERS) is a national program monitoring the safety of vaccines after they 
are licensed.  VAERS is managed by the U.S. Centers for Disease Control and Prevention (CDC) and the U.S. Food and 
Drug Administration (FDA).  
 
Vaccines prevent serious illnesses and even death in persons who receive them.  Before a vaccine is licensed, FDA takes 
steps to make sure the vaccine is safe.  FDA requires a vaccine goes through extensive safety testing.  After a vaccine is 
licensed, VAERS is one of the mechanisms used to monitor for any problems, or “adverse events,” that happen after 
vaccination.  
 
Not all events reported to VAERS are caused by the vaccine.  Even though careful studies are done before a vaccine is 
licensed, rare adverse events may not be found until a vaccine is given to millions of people with different backgrounds 
and medical histories.  By continued monitoring, VAERS helps to make sure that the benefits of vaccines are far greater 
than the risks. 
 
Anyone who receives a vaccine should be informed about both the benefits and risks of vaccination.  Any questions or 
concerns should be discussed with a health care provider.  
 
Limitations and Usefulness of VAERS    
o VAERS is unable to determine that a vaccine caused or did not cause an adverse event.   
o Sometimes people who are vaccinated get sick from another cause unrelated to the vaccine.  
o Even though VAERS cannot determine a vaccine caused an adverse event, it can give FDA and CDC important 
information that might signal a problem.   
o If it looks as though a vaccine might be causing an adverse event, FDA and CDC will investigate further.  
 
Does VAERS Provide Medical Advice?     
No, VAERS does not provide medical advice.  Medical advice should be provided by the health care provider. 
 
Who Can Report to VAERS? 
o Parents 
o Patients 
o Health care Providers 
o Others   
    
FDA and CDC encourage anybody who experiences a problem after vaccination to report to VAERS.  Health care 
providers are required by law to report certain problems.  The National Childhood Vaccine Injury Act (NCVIA) 
requires health care providers to report: 
o Any event listed by the vaccine manufacturer as a contraindication to subsequent doses of the vaccine. 
o Any event listed in the Reportable Events Table that occurs within the specified time period after vaccination.  
 
Why Should I Report to VAERS? 
o Reporting gives valuable information that helps CDC and FDA make sure that vaccines are safe. 
o Reporting strengthens VAERS so it can be used to assess public health response to vaccines.  
o Reporting allows for evaluating public health prevention and control measures.  
 
Remember, no vaccine (or any medicine) is completely free of risk, and adverse events are possible.  If you have an 
adverse event after a vaccine, please report to VAERS.  Each report is important! 
 
VAERS forms can be ordered by calling 1-800-822-7967, or download a printable copy of the VAERS form from the 
VAERS and CDC websites.  For more information send e-mail inquiries to info@vaers.org or contact Terri Thornton a 
1-800-831-6293, ext. 2 or at Teresa.Thornton@idph.iowa.gov. 
  
 
 Implementing Economic Order Quantity (EOQ) 
The Centers for Disease Control and Prevention (CDC) has implemented Economic Order Quantity (EOQ) for 
Vaccines for Children Program providers.  EOQ balances the size and frequency of provider vaccine orders, timing of 
orders, vaccine availability, and reduces costs associated with vaccine storage/handling errors.  EOQ does not 
change the process for submitting a vaccine order, just the timing of when vaccine orders are placed.  
 
Tips for Vaccine Ordering 
What to consider before placing a vaccine order: 
o How many doses of vaccine are in inventory? 
o What vaccines may expire before the next ordering frequency? 
o How many vaccine doses were administered during the same timeframe last year? 
o What seasonal events (e.g., school physicals, kindergarten round up) are scheduled? 
o What specialty clinics (school-based clinics) are planned? 
o When can the next order be submitted based on the clinic established vaccine order frequency? 
 
If you have additional questions regarding EOQ contact Janean Iddings at 1-800-831-6293, ext. 5 or 
Janean.Iddings@idph.iowa.gov. 
 
 
 
Updated Vaccine Storage and Handling Template is Now Available 
Protecting your vaccine supply is critical.  Failure to adhere to recommended specifications for vaccine storage and 
handling can reduce potency, resulting in an inadequate immune response in the patients.  Vaccine quality is the 
responsibility of all those that handle vaccine from the time a vaccine is manufactured until administration.  To protect 
vaccine inventory and minimize loss, health care providers should develop and routinely review storage and handling 
plans, provide staff education, and exercise plans to respond to improper storage and handling events.  The Iowa 
Department of Public Health has updated the Vaccine Storage and Handling Template to include new recommendations 
and requirements.  Click here to access the template.  
 
 
 
 
 
 
 
 
 
 
Vaccines for Children Program (VFC)  
Vaccine Storage and Handling 
 
2011-2012 Influenza Resources 
o Iowa Immunization Program 2011-2012 Influenza Chart 
o 2011-2012 Influenza Vaccine Information Statements 
o CDC 2011-2012 Seasonal Influenza Information 
MMRW articles for the 2011-2012 influenza season 
o Prevention & Control of Seasonal Influenza recommendations from the ACIP, 2011  
o Influenza Vaccination Coverage Among Health-Care Personnel --- United States, 2010--11 Influenza Season 
o Influenza Vaccination Coverage Among Pregnant Women --- United States, 2010--11 Influenza Season 
 
Prevnar and Influenza Vaccine:  CDC has posted additional information about the potential risk of febrile seizures 
when inactivated influenza vaccine and PCV13 are administered simultaneously.  After thoroughly evaluating the 
available information, CDC has determined that no changes in the childhood immunization schedule are necessary at 
this time.  This information may be useful in explaining this risk to patients who read the brief note about it on the 
Inactivated Influenza vaccine VIS.  Additional information is available at 
http://www.cdc.gov/vaccinesafety/Concerns/FebrileSeizures.html 
 
 Bulk quantities of the 2011-12 Influenza Vaccine Pocket Guides and PPSV Pocket Guides 
available--FREE!--from the National Influenza Vaccine Summit  
To aid in efforts to vaccinate against influenza and pneumococcal disease, readers are invited to 
place orders now for bulk quantities of the National Influenza Vaccine Summit's 2011-12 Influenza 
Vaccine Pocket Information Guide and Pneumococcal Polysaccharide Vaccination (PPSV) Pocket 
Guide.  Both are free--you can order them in the hundreds or thousands! 
There is no cost for the pocket guides, shipping, or handling within the U.S. 
Place your order at http://www.preventinfluenza.org/pocketguides  
 
National Influenza Vaccination Week (NIVW) is a national observance established to highlight the importance of 
continuing influenza vaccination, as well as fostering greater use of flu vaccine after the holiday season into January and 
beyond.  NIVW 2011-2012 is scheduled for December 4-10, 2011. 
 
Epidemiology and Prevention of Vaccine-Preventable Diseases 2011, Ten-Module Series:  This comprehensive 
immunization course provides the most current information in the constantly changing field of immunization.  It is 
updated annually to provide the latest recommendations from the ACIP.  Each of the 10 sessions is 60 to 90 minutes in 
length and includes case studies and a discussion of frequently asked questions.  The web-on-demand course is now 
available, and the DVD is also available for ordering.  Continuing education is available, and additional information is 
provided in each session.  For information and updates on other courses, please visit the National Center for 
Immunization and Respiratory Diseases (NCIRD) Education and Training web page. 
 
Autism 101 for Immunization Advocates-Friday, October 14, 2011, 2:00 PM Eastern Daylight Time 
This training is for Immunization advocates to listen to the concerns parents raise regarding vaccines and 
autism.  Parents may have heard scary things about vaccines on TV or from friends, and their fears are very real.  It’s our 
job as medical and public health professionals to explain the science regarding vaccines and autism clearly and concisely.  
Please join Every Child By Two as they host Alison Singer from the Autism Science Foundation who will present an 
overview of autism including the very latest research regarding early diagnosis, interventions and potential causes.  She 
will also review the CASE Method, which combines emotional and scientific talking points aimed at swaying parents’ 
emotional response regarding vaccines and help them face the issue more logically.   
Registration Link: https://cc.readytalk.com/r/grnrshog3l58 
Immunization Resources 
